Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873441 | 1.00 | LMNA (0.59) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL7446933 | 1.00 | LMNA (0.59) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL12653614 | 1.00 | LMNA (0.59) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL3309097 | 1.00 | LMNA (0.59) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5873474 | 1.00 | LMNA (0.59) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL13408163 | 0.97 | — | — | |
| SCHEMBL16853123 | 0.91 | GABRR1 (0.55) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL16853370 | 0.91 | GABRR1 (0.55) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL16853138 | 0.91 | GABRR1 (0.55) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5873455 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| EP-0871440-B1 | TREATMENT OF NEGATIVE AND COGNITIVE SYMPTOMS OF SCHIZOPHRENIA WITH GLYCINE UPTAKE ANTAGONISTS | JAVITT DANIEL C (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20020161048-A1 | Glycine substitutes and precursors for treating a psychosis | GLYTECH, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6355681-B2 | ADMINISTERING TO HUMAN A SUBSTITUTE FOR GLYCINE AT THE GLYCINE-SITE OR A PRECURSOR OF SUBSTITUTE OR A GLYCINE PRECURSOR, IN AN AMOUNT SUFFICIENT TO POTENTIATE NMDA RECEPTOR-MEDIATED NEUROTRANSMISSION | GLYTECH, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20020013364-A1 | GLYCINE SITE FULL AGONIST FOR TREATING A PSYCHOSIS | GLYTECH, INC. | 2002-01-31 | — | — | US | disclosed |
| EP-0871440-A4 | TREATMENT OF NEGATIVE AND COGNITIVE SYMPTOMS OF SCHIZOPHRENIA WITH GLYCINE UPTAKE ANTAGONISTS | JAVITT DANIEL C (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5837730-A | REDUCING THE SIDE-EFFECT OF GLYCINE FOR TREATING NERVOUS SYSTEM DISORDER, PSYCHOLOGICAL DISORDER | GLYTECH, INC., A CORP. OF NEW YORK | 1998-11-17 | — | — | US | disclosed |
| EP-0871440-A1 | TREATMENT OF NEGATIVE AND COGNITIVE SYMPTOMS OF SCHIZOPHRENIA WITH GLYCINE UPTAKE ANTAGONISTS | Javitt, Daniel, C. (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0789036-A2 | Processes for preparing (meth)-acrylic polymers having functional groups at the chain ends | Kaneka Corporation (JP) | 1997-08-13 | — | — | EP | disclosed |
| WO-1997020553-A1 | TREATMENT OF NEGATIVE AND COGNITIVE SYMPTOMS OF SCHIZOPHRENIA WITH GLYCINE UPTAKE ANTAGONISTS | JAVITT DANIEL C (US) | 1997-06-12 | — | — | WO | disclosed |